Development of a novel immunomodulatory pyridone for the treatment of heart failure with preserved ejection fraction
Ended Project Grant Awarded Last action
- Award ID
- R44HL145833
- Recipient
-
I-Cordis, LLC UEI D2AUZ7D5DXJ1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,097,416
Award facts
- Assistance listing
- 93.350 National Center for Advancing Translational Sciences
- Completion date
- Originally
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Description
- Abstract
- Heart failure with preserved ejection fraction (hfpef) is one of the major drivers of healthcare costs in the western world and arguably the largest unmet need in cardiology. Currently, there are no FDA approved drugs to treat the vast majority of patients with hfpef. Recently, the phase II pirouette trial showed that the immunomodulatory drug pirfenidone, marketed for the treatment of a rare lung disease, has marked beneficial effects in patients with hfpef. Unfortunately, pirfenidone is a suboptimal drug. In fact, because of its poor pharmacokinetics, patients need to take 2 large pills three times a day and they often develop mild to moderate side effects that lead to dose reduction or discontinuation of treatment (38% of treated patients had to discontinue pirfenidone in the pirouette trial). Moreover, from a commercial point of view, pirfenidone has no intellectual property protection and therefore pharmaceutical companies have no incentive to develop IT for further applications. I-cordis has pegylated pirfenidone to obtain "pegydone", a new molecular entity with better exposure, less toxicity and superior therapeutic effects than pirfenidone. I-cordis has completed proof of concept studies in rodent models. In this sbir phase II grant i-cordis requests support to complete critical pre-clinical studies to DE-risk its drug development effort in the eyes of potential investors. Following completion of the phase II grant, the company plans to raise dilutive funding to complete IND filing, and progress through clinical trials, FDA approval and commercialization of pegydone as a prescription drug for the treatment of hfpef.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $739,896 | |
| Amendment | $739,896 | |
| Amendment | $808,812 | |
| Original award | $808,812 |
Quick answers
Who received award R44HL145833?
R44HL145833 was awarded to I-Cordis, LLC by National Heart Lung and Blood Institute (National Institutes of Health) on September 18, 2019.
How much is award R44HL145833 worth?
$3,097,416 has been obligated on R44HL145833.
Which agency awarded R44HL145833?
National Heart Lung and Blood Institute (National Institutes of Health) awarded R44HL145833, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award